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INTRODUCTION
Cachexia is a complex metabolic and nutritional syndrome characterized by a massive loss of adipose tissue and skeletal muscle (1). The term cachexia is coined from the Greek words 'kakos' and 'hexis' for 'bad condition' (2) . Cachexia is encountered not only in cancer, but also in other life-threatening diseases such as acquired immunodeficiency syndrome, rheumatoid arthritis, chronic obstructive pulmonary disease, and organ failure (1). In cancer patients, the cachectic syndrome is a major cause of morbidity and mortality. Progressive cachexia indicates poor prognosis with a shorter survival time, and ultimately accounts for nearly 20% of all cancer deaths (3, 4) . The rate and amount of weight loss are directly related to survival in cancer patients (5) . Cachexia occurs with a frequency of 83 to 87% in patients with pancreatic and gastric cancer, 48 to 61% in patients with cancers of the colon, prostate, lung, head and neck, and unfavorable non-Hodgkins lymphoma, and 31 to 40% in patients with breast cancer, sarcomas, leukemia, and favorable subtypes of non-Hodgkins lymphoma (4) .
Cachexia involves the secretion of tumor-derived catabolic factors along with hostderived pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), IL-1βҏ and interferon-γ (IFN-γ). Tumor-derived catabolic factors such as lipid-mobilizing factor (LMF) lead to changes in host metabolism and energy expenditure, resulting in cancer cachexia (6) . LMF is a toxohormone that up-regulates degradative pathways in adipose tissue, and increases fat metabolism in cachectic animals and humans (6) . Glucocorticoids and tumor-derived proteolysis-inducing factor (PIF) also play critical roles in this condition (7) . The consequences of the significant weight loss and the massive loss of proteins are multiple and severe, ranging from impairment of immune function to poor outcome of chemotherapy, fatigue, respiratory muscle weakness and markedly reduced quality of life (4, 5) .
There is limited understanding of the pathogenesis of this lethal syndrome, and no known cure, since mechanisms underlying its manifestation are not defined clearly enough to design effective therapeutic strategies. As a result therapy is ineffective, and there is an urgent need to identify new targets to develop effective therapies. The ability to detect the onset or presence of cachexia non-invasively, and detect response to treatment, is central to developing new therapies. Significant abnormalities in carbohydrate, lipid and protein metabolism are observed with cachexia, and are a major cause for the associated profound weight loss (5).
Non-invasive clinically translatable techniques such as magnetic resonance spectroscopy (MRS) and positron emission tomography (PET) with their respective metabolic imaging capabilities provide the opportunity to investigate the interaction between cancer cells and the tumor, the 'tumor macroenvironment' to identify stages in the cachexia-cascade.
With its clinical translatability, relatively high sensitivity and ability to detect metabolites such as lipids, lactate, and total choline (tCho), which consists of free choline (Cho), The presence of cachexia in our experimental model was confirmed by weight loss and an increase in the expression levels of two markers of muscle protein degradation, Atrogin-1 (mouse atrophy gene 1) and MuRF1 (muscle RING finger 1). Atrogin-1 and MuRF1 are two skeletal muscle specific ubiquitin ligases required in protein breakdown (8) , and the expression levels of these ligases increases with cachexia, and (5, (8) (9) (10) . The presence of cachexia was additionally confirmed by the analysis of lipid content in serum from cachectic and non-cachectic tumor bearing mice (11, 12) .
In vivo, cachectic tumors were characterized by increased tCho and 18 FDG uptake compared to non-cachectic ones, and induced a profound depletion of triglycerides in normal tissue that was not observed with non-cachectic tumors. Cachexia also resulted in increased 18 FDG uptake in the brain and lung. An increase of PC and succinate along with a decrease of creatine were detected in high-resolution spectra of cachectic tumor extracts. The higher choline kinase mRNA levels observed in MAC16 cells and tumors were consistent with higher PC observed in tumor extract spectra and the increased tCho observed in vivo. These metabolic patterns may represent new noninvasive biomarkers and targets in the detection, management, and treatment of this condition. (14) . Signals at ~ 3.2 ppm from tCho and at 1.3 ppm from lipids with some contribution from lactate that overlaps with the lipid signal were detected in localized proton spectra.
MATERIALS AND METHODS

Cell
A home-built volume coil was used to acquire whole-body Quantitative maps of tCho and lactate+lipids were generated from the spectroscopic images using unsuppressed water signal as an internal reference (15) . Quantitative metabolic maps were generated using in-house IDL programs. Integrals of the metabolites of interest were determined and normalized to the tumor weight. To determine concentrations, peak integration from 1 H spectra for all metabolites studied was compared to the internal standard. 
High
Statistical analysis.
Values displayed are mean ± SEM. Statistical significance was evaluated using the Student's t-test; P < 0.05 was considered significant.
RESULTS
Confirming the presence of cachexia. Cachectic MAC16 and non-cachectic MAC13
tumors displayed comparable growth rates and histology. However, as shown in Figure   1a , MAC16 tumors induced significant weight loss, confirming the induction of cachexia. 
Quantitative tCho and lactate+lipids data acquired from multiple animals are summarized in Figures 3d-f . A significant increase of tCho was observed in MAC16 compared to MAC13 tumors (Figure 3d ). There was no significant difference in lactate+lipids obtained from within the tumor (Figure 3e ), but a significant decrease of lactate+lipids around the tumor periphery in MAC16 compared to MAC13 tumors (Figure 3f ). The lactate+lipids signal around the periphery of the tumor was from subcutaneous fatty tissue that is found between the tumor and the fold of the skin, which decreased as the lipids decreased in normal tissue of cachectic mice, as discussed subsequently. and is closely related to malignant transformation, invasion, and metastasis (24, 25) .
Elevated PC and tCho have been previously detected by MRS studies in human lung, colon, prostate, and breast tumors, as well as in derived epithelial cell lines (21, 23) . PC is a precursor as well as a metabolic breakdown product of the major membrane component phosphatidylcholine. Here we have identified a previously unknown association between choline metabolism and cachexia. We found that mRNA for choline kinase, a cytosolic enzyme that catalyzes the phosphorylation of choline to PC by ATP in the presence of magnesium, was significantly elevated in MAC16 cells and tumors, identifying it as a potential novel target to investigate in the treatment of cachexia.
Increased
18
FDG uptake is used to detect metabolically active cancers. 18 FDG is taken up by the cells via glucose transporters and phosphorylated by the first enzyme of the glycolysis, the hexokinase. 18 FDG PET can be used in vivo to identify tumor tissues, since cancer cells exhibit a higher glycolytic activity, leading to a higher uptake of 18 FDG (26). Here we found that similar to tCho, 18 FDG uptake was more than two-fold higher in cachectic MAC16 tumors compared to non-cachectic MAC13 tumors, suggesting that exceedingly high 18 FDG uptake may be another risk factor for the induction or presence of cachexia. Although high 18 FDG uptake is usually associated with increased glycolytic activity (26, 27), we did not observe a significant difference in lactate levels between MAC13 and MAC16 tumors. Interestingly we did detect a higher level of succinate in the cachectic tumors. Since succinate is produced in the tricarboxylic acid cycle (TCA) The search for noninvasive biomarkers of cachexia has been ongoing for several years.
One 1 H MRS-based search for cachexia biomarkers in the sera of C26 adenocarcinomabearing mice identified very low-density lipoproteins along with hypoglycemia as serum markers (11) . An assessment of hepatic and skeletal muscle bioenergetic status using 31 P MRS demonstrated that progressive cancer cachexia was associated with depletion of energy stores in liver and skeletal muscle (30) . Increased hepatic Pi/ATP ratio was detected by 31 P MRS, and occurred early in the disease process (30) . The liver is a central organ in the pathogenesis of cachexia (31) . Increased Pi and a rapid removal of phosphomonoesters were identified with 31 P MRS in a rat cancer model of cachexia. Cachexia also induced enhanced hepatic gluconeogenic activity (32) . While the use of 31 
